Theravance Biopharma(TBPH) - 2023 Q2 - Earnings Call Presentation

20 $325 Million Capital Return Program On Track to Complete Program by Year-End ~$264M completed overall; ~$61M remaining in capital return program Up to$250M of Sales-based milestones12 between 2023-2026: Long-Term Value • US royalties return after Jan. 1, 2031 MSA, multiple system atrophy; nOH, neurogenic orthostatic hypotension. | --- | --- | --- | --- | |-------|----------------------------------------------------------------|-------------------------------------------------------------------|-------| ...